Global Biotech Breakthroughs

Sichuan Kelun-Biotech Biopharmaceutical

Market Cap: HK$110.6b

A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally.

CARsgen Therapeutics Holdings

Market Cap: HK$9.4b

An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.

Madrigal Pharmaceuticals

Market Cap: US$11.9b

A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.

Beijing Luzhu Biotechnology

Market Cap: HK$3.9b

A biotechnology company, focuses on the research and development, production, and sale of human vaccines and therapeutic biologics to prevent and control infectious diseases, and treat cancer and autoimmune diseases in Mainland China.

Dizal (Jiangsu) Pharmaceutical

Market Cap: CN¥25.5b

A commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and hematologic disorders.

Syndax Pharmaceuticals

Market Cap: US$1.8b

A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.

Guangzhou Innogen Pharmaceutical Group

Market Cap: HK$5.6b

Engages in the development of drugs.

HansBiomed

Market Cap: ₩410.7b

Engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies.

Akeso

Market Cap: HK$107.4b

A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.

AnaptysBio

Market Cap: US$1.7b

A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.

Marker Therapeutics

Market Cap: US$23.3m

A clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States.

Ardelyx

Market Cap: US$1.5b

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.

3billion

Market Cap: ₩323.6b

Develops technology for rare disease drug discovery using bioinformatics and machine learning technology.

BioPorto

Market Cap: DKK 616.4m

An in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia.

Cutia Therapeutics

Market Cap: HK$1.5b

An investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong.

Mesoblast

Market Cap: AU$2.7b

Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.

ARS Pharmaceuticals

Market Cap: US$788.5m

A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.

Capricor Therapeutics

Market Cap: US$1.7b

A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.

Lineage Cell Therapeutics

Market Cap: US$324.1m

A clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally.

Intellia Therapeutics

Market Cap: US$1.8b

Operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.

RenovoRx

Market Cap: US$39.7m

A clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.

Aldeyra Therapeutics

Market Cap: US$93.5m

A biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.

Tenaya Therapeutics

Market Cap: US$167.6m

A clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.

Ascentage Pharma Group International

Market Cap: HK$15.3b

A clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.

Achieve Life Sciences

Market Cap: US$481.5m

A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.

DBV Technologies

Market Cap: €985.4m

A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.

Viridian Therapeutics

Market Cap: US$1.9b

Engages in discovering, developing, and commercializing treatments for serious and rare diseases.

AC Immune

Market Cap: US$280.7m

A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.

Longeveron

Market Cap: US$24.0m

A clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.

Arcutis Biotherapeutics

Market Cap: US$2.6b

A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.

Quince Therapeutics

Market Cap: US$17.9m

A biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases.

Citius Oncology

Market Cap: US$74.1m

Focuses on the development and commercialization of innovative targeted oncology therapies.

CG Oncology

Market Cap: US$5.7b

A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.

Oxford Biomedica

Market Cap: UK£747.3m

A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.

Insmed

Market Cap: US$23.0b

Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.

Larimar Therapeutics

Market Cap: US$360.1m

A clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.